EconPapers    
Economics at your fingertips  
 

Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability

Cornelia Jäkel, Frank Bergmann, Reka Toth, Yassen Assenov, Daniel Duin, Oliver Strobel, Thomas Hank, Günter Klöppel, Craig Dorrell, Markus Grompe, Joshua Moss, Yuval Dor, Peter Schirmacher, Christoph Plass, Odilia Popanda and Peter Schmezer ()
Additional contact information
Cornelia Jäkel: German Cancer Research Center (DKFZ)
Frank Bergmann: University Hospital Heidelberg
Reka Toth: German Cancer Research Center (DKFZ)
Yassen Assenov: German Cancer Research Center (DKFZ)
Daniel Duin: German Cancer Research Center (DKFZ)
Oliver Strobel: University Hospital Heidelberg
Thomas Hank: University Hospital Heidelberg
Günter Klöppel: Technical University Munich
Craig Dorrell: Oregon Health and Science University
Markus Grompe: Oregon Health and Science University
Joshua Moss: The Hebrew University-Hadassah Medical School
Yuval Dor: The Hebrew University-Hadassah Medical School
Peter Schirmacher: University Hospital Heidelberg
Christoph Plass: German Cancer Research Center (DKFZ)
Odilia Popanda: German Cancer Research Center (DKFZ)
Peter Schmezer: German Cancer Research Center (DKFZ)

Nature Communications, 2017, vol. 8, issue 1, 1-10

Abstract: Abstract Pancreatic acinar cell carcinoma (ACC) is an aggressive exocrine tumor with largely unknown biology. Here, to identify potential targets for personalized treatment, we perform integrative genome-wide and epigenome-wide analyses. The results show frequently aberrant DNA methylation, abundant chromosomal amplifications and deletions, and mutational signatures suggesting defective DNA repair. In contrast to pancreatic ductal adenocarcinoma, no recurrent point mutations are detected. The tumor suppressors ID3, ARID1A, APC, and CDKN2A are frequently impaired also on the protein level and thus potentially affect ACC tumorigenesis. Consequently, this work identifies promising therapeutic targets in ACC for drugs recently approved for precision cancer therapy.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-017-01118-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-01118-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-01118-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-01118-x